Full Text
PCN87 The Cost Effectiveness of Cetuximab (Erbitux) in the Third Line Treatment of Metastatic Colorectal Cancer in the UK

Abstract

Authors

R. Perard Y. Samyshkin A.L.G. Guillermin

Back to Volume 14, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×